"It's a new antibody that has a long half-life so each treatment can be prolonged."

AZD0780 — the first oral PCSK9 inhibitor — is lowering LDL cholesterol levels, report phase 1 trial investigators, but specialists are questioning the early findings.

A new oral formulation of a PCSK9-inhibitor, cholesterol-lowering drug has shown encouraging results in a phase 2 study.

Lerodalcibep, a third-generation PCSK9 inhibitor, reduced LDL by more than 50% vs placebo in patients with or at a high risk for CVD in the phase 3 LIBerate-HR trial.

A large case-control study using genetic proxies for PCSK9 inhibitors may help alleviate concerns that the dyslipidemia agents could promote adverse cardiac remodeling and heart failure.

"Go early and go low" is an expert's response to the imaging results from PACMAN-AMI showing plaque reduction after AMI patients received alirobumab.

An investigational PCSK9 inhibitor with a different mechanism from existing drugs in this class has been shown to safely and effectively lower cholesterol levels.

The study suggests that "PCSK9 inhibition is causally associated with reduced risk of psoriasis" and has implications for prevention and possibly treatment of psoriasis, the investigators say.

Effects observed in inflammation and improved clinical outcomes

Question now is whether routine early treatment will translate to better clinical outcomes

Also in TTHealthWatch: Mild hypertension treatment in pregnancy

Recent developments of interest in cardiovascular medicine

PCSK9 inhibitors were associated with a lower risk for nonmelanoma skin cancer in older adults with atherosclerotic cardiovascular disease, in a retrospective cohort study.

Clinical trial affirms LDL reduction atop statins in pediatric familial hypercholesterolemia

A protein engineering toolkit for molecular design // Engineering enzymes to break down plastic with ProtGPT2, OmegaFold, TemStaPro // Designing drugs with RFDiffusion, ProteinMPNN, ColabFold

Patient acceptance could be an advantage, researchers say

Experiments in mice show that designed epigenome editors that contain domains of transcriptional repressors can enable stable epigenetic silencing of Pcsk9, a gene with a role in cholesterol homeostasis, without inducing DNA breaks.

Recent developments of interest in cardiovascular medicine

In a closely fought patent battle between PCSK9 rivals Amgen and Sanofi/Regeneron, the Supreme Court ruled unanimously on Thursday that Amgen cannot monopolize the market for any and every antibody that binds to areas of the sweet spot of PCSK9. The win for Sanofi and Regeneron is a setback for

The powerful LDL-lowering agents aren't being used to their fullest potential, but giving them early to STEMI patients along with high-intensity statins would help amend that, researchers say.